Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy

REFERENCES

• Bartlett J, Demasi R, Quinn J, Moxham C, Rousseau F. Meta-analysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1 infected adults. In: Proceedings of the Seventh Conference on Retroviruses and Opportu-nistic Infections; January 2000; San Francisco, CA. Ab-stract 1519.
   Google Scholar
• Loutfy MR, Walmsley SL. Salvage therapy in HIV infection. Exprt Opin Pharmacother. 2002;3: 81–90.
   PubMedGoogle Scholar
• Smith GHR, Klein M, Leblanc R, MacCleod J, Routy JP, Lalonde R. Salvage therapy for HIV-1 infection with lopinavir/ritonavir (LOP/RIT), saquinavir-SGC (SQR), and nucleoside analogues in patients having failed all three antiretroviral classes. In: Proceedings of the 10th Canadian Conference on HIV/AIDS Research; May 2001; Toronto, Canada. Abstract 1212.
   Google Scholar
• Ruiz L, Ribera E, Bonjochl A, et al. Virological and immuno-logical benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month follow-up). In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 421–W.
   Google Scholar
• Helliger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000 mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibi-tor-experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). In: Pro-ceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Ab-stract 421–W.
   Google Scholar
• Staszewski S, Dauer B, Stephan C, Gute P, Klauke S, Sturmer M. Switch to a simple boosted double protease inhibitor regimen of lopinavir/r and saquinavir without re-verse transcriptase inhibitors after multiple therapy fail-ures. In: Proceedings of the XIV International AIDS Confer-ence; July 2002; Barcelona, Spain. Abstract TuPeB4474.
   Google Scholar
• Zala C, Patterson P, Coll P, et al. Virological response and safety at 48 weeks of double boosted protease inhibitors with Lopinavir/R plus either Saquinavir or Amprenavir in heavily pretreated HIV infected patients. In: Proceedings of the XIV International AIDS Conference; July 2002; Barcelona, Spain. Abstract TuPeB4492.
   Google Scholar
• Khanlou H, Graham E, Brill M, Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy [letter]. AIDS. 2002;16:797–798.
   PubMed Web of Science ®Google Scholar
• Stein AJ, Brothers CH, Scott TR. Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV. Clin Ther. 200123: 513–515.
   Google Scholar
• Duval X, Race E, Lamotte C, et al. Inhibitory quotient and efficacy of amprenavir-lopinavir containing HAART in heavily pretreated HIV infected patients. In: Proceedings of the Second International Workshop on Clinical Pharmacol-ogy of HIV Therapy; April 2001; Noordwijk, The Nether-lands. Abstract 5.11.
   Google Scholar
• Peytavin G, Lamotte C, Duval X, et al. Amprenavir (APV) plasma concentrations are dramatically decreased by as-sociation with ABT378/r in HIV-infected patients. In: Pro-ceedings of the Second International Workshop on Clinical Pharmacology of HIV Therapy; April 2001; Noordwijk, The Netherlands. Abstract 1.14.
   Google Scholar
• Solas C, Quinson AM, Couprie C, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 440–W.
   Google Scholar
• Baldini F, Rizzo MG, Hoetelmans R, et al. A prospective study of deep salvage therapy with lopinavir/r, amprenavir, and NRTIs: final 24-week data, pharmacokinetics, and as-sociation of drug levels/drug susceptibility with virologic response. In: Proceedings of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA. Abstract 423–W.
   Google Scholar
• Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS. 2002;16:296–297.
   Google Scholar
• Romer K, Fatkenheuer G, Kamps R, Salzberger B, Burger D. Pharmacokinetics of amprenavir and lopinavir in combi-nation with ritonavir and nevirapine in highly pretreated HIV infected patients. In: Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV In-fection; October 2001; Athens, Greece. Abstract P166.
   Google Scholar
• Fatkenheuer G, Romer K, Kamps R, Salzberger B, Burger D. Pharmacokinetics of amprenavir and lopinavir in combi-nation with nevirapine in highly pretreated HIV-infected patients. AIDS. 200115: 2334–2335.
   Google Scholar
• Hsu A, Bertz R, Ashbrenner E, et al. Interaction of ABT-378/ritonavir with protease inhibitors in healthy volunteers. In: Proceedings of the First International Workshop on Clinical Pharmacology of HIV Therapy; March 2000; Noordwijk, The Netherlands. Abstract 2.4.
   Google Scholar
• Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of lopinavir and amprenavir in combination with ritonavir. In: Proceedings of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens, Greece. Abstract P170.
   Google Scholar
• van Heeswijk RP, Hoetelmans RM, Harms R, et al. Simulta-neous quantitative determination of the HIV protease in-hibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci AppL 1998;719:159–168.
   PubMed Web of Science ®Google Scholar
• Lamotte C, Duval X, Peytavin G, Farinotti R. Amprenavir (APV) plasma concentrations are dramatically increased by association to ritonavir (RTV) baby-doses in HIV infected patients: possible combination with efavirenz (EFV). In: Proceedings of the XIII International AIDS Conference; July 2000; Durban, South Africa. Abstract WePeB123.
   Google Scholar
• Molla A, Mo H, Vasavanonda S, et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother. 2002;46:2249–2253.
   PubMed Web of Science ®Google Scholar
• Miller V, Staszewski S, Sabin C, et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human im-munodeficiency virus load. J Infect Dis. 1999;180:530–533.
   PubMed Web of Science ®Google Scholar